Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,491,678
  • Shares Outstanding, K 20,342
  • Annual Sales, $ 98,430 K
  • Annual Income, $ -118,960 K
  • EBIT $ -138 M
  • EBITDA $ -134 M
  • 60-Month Beta 1.17
  • Price/Sales 17.90
  • Price/Cash Flow N/A
  • Price/Book 16.11

Options Overview Details

View History
  • Implied Volatility 80.29% (+4.18%)
  • Historical Volatility 136.79%
  • IV Percentile 11%
  • IV Rank 2.75%
  • IV High 620.58% on 04/16/25
  • IV Low 65.00% on 08/28/25
  • Expected Move (DTE 8) 6.33 (9.09%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 996
  • Volume Avg (30-Day) 1,710
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 33,389
  • Open Int (30-Day) 33,761
  • Expected Range 63.31 to 75.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.76
  • Number of Estimates 6
  • High Estimate -1.98
  • Low Estimate -4.09
  • Prior Year -2.25
  • Growth Rate Est. (year over year) -22.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.50 +11.22%
on 03/09/26
75.67 -8.14%
on 02/23/26
-1.49 (-2.10%)
since 02/12/26
3-Month
33.40 +108.11%
on 01/30/26
75.67 -8.14%
on 02/23/26
+14.81 (+27.07%)
since 12/12/25
52-Week
6.45 +977.67%
on 04/09/25
75.67 -8.14%
on 02/23/26
+57.21 (+465.12%)
since 03/12/25

Most Recent Stories

More News
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”)...

NKTR : 69.20 (-5.63%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR

NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. ...

NKTR : 69.20 (-5.63%)
NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options

NKTR : 69.20 (-5.63%)
Nektar Therapeutics (NKTR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR ) investors concerning the Company’s possible...

NKTR : 69.20 (-5.63%)
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR ) on behalf of investors concerning the Company’s...

NKTR : 69.20 (-5.63%)
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NKTR

The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR ) for violations of §§10(b) and 20(a)...

NKTR : 69.20 (-5.63%)
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: ...

NKTR : 69.20 (-5.63%)
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

NEW YORK , March 9, 2026 /PRNewswire/ --

NKTR : 69.20 (-5.63%)
NKTR Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Against Nektar Therapeutics

SAN DIEGO , March 9, 2026 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ:...

NKTR : 69.20 (-5.63%)
Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15,...

NKTR : 69.20 (-5.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 77.04
2nd Resistance Point 75.22
1st Resistance Point 74.28
Last Price 69.20
1st Support Level 71.52
2nd Support Level 69.70
3rd Support Level 68.76

See More

52-Week High 75.67
Last Price 69.20
Fibonacci 61.8% 49.23
Fibonacci 50% 41.06
Fibonacci 38.2% 32.89
52-Week Low 6.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar